Limbic encephalitis was firstly described by Brierley in 1960 1 and was characterized as an inflammatory disorder involving the hippocampi, amygdala, frontobasal and insular regions, with a spectrum of symptoms, most commonly characterized by a subacute progressive impairment of short-term memory, psychiatric features and seizures. While in some cases it appears to exclusively involve limbic regions, it has become clear that several clinical features implicate involvement of areas other than the limbic system. For this reason, the authors prefer the term autoimmune encephalitis (AIE).
His spouse noticed that over the last two months he had developed irritability and forgetfulness, which was associated with frequent involuntary jerks of the right side of the face and ipsilateral arm. There was no fever or headache. On examination, he was confused and showed a marked deficit in anterograde memory. After a normal Computerized Tomography (CT) scan, he was treated with acyclovir and phenytoin. Despite this, ongoing jerks were noted.
The differential diagnosis of this case is discussed in the Table 1 2-4 and the results of investigation in Table 2 . Given the subacute history of cognitive decline and the presence of focal seizures (likely faciobrachial dystonic seizures) along with the MRI changes, AIE was suspected 5, 6 . Also taking into consideration the age of the patient, a normal CSF and serum hyponatremia, antibodies against the VGKCcomplex 7 were requested, and the results were strongly positive. A body CT showed no underlying neoplasm. The patient was treated with high-dose steroids and made a good recovery, returning to work after four months.
The key points for the definite diagnosis were:
(1) subacute history of cognitive decline, irritability and seizures that were refractory to antiepileptic drugs; (2) presence of faciobrachial dystonic seizures, which are highly characteristic of antibodies against the LGI1 (leucine-rich glioma inactivated 1) subunit of the VGKC-complex;
(3) MRI with medial temporal abnormalities in association with a normal CSF evaluation; (4) serum hyponatremia without an alternative explanation.
In the next sections, cardinal clinical signs will be presented according to each underlying antibody, and a diagnostic approach will be proposed in order to facilitate the clinical recognition of AIE.
DESCRIPTION Pathophysiology
For all AIE, a division can be made regarding the location of the causal antigens and, therefore, likely disease mechanisms. Generally, antibodies to intracellular antigens are associated with underlying malignancies and, in contrast, those against membrane antigens usually do not reflect the presence of a tumour. However, some membrane autoantibodies may be associated with tumours (Fig 1) . Hence, in all patients presenting with suspected AIE, a comprehensive search for an underlying malignancy is considered.
Antibodies to intracellular antigens (inside the neuron) -Hu, Ma2, CV2, Antiphiphysin, glutamic acid decarboxylase (GAD) These are usually associated with cytotoxic T cell mechanisms. The neuronal damage seems to be irreversible and the prognosis is usually poor. One exception appears to exist in patients with GAD antibodies: these patients may have AIE, epilepsy or other neurological syndromes, tumours are uncommon, and recovery is possible although patients are often less responsive to immunotherapies 5 .
Antibodies to cell membrane surface antigens -VGKC-complex (LGI1, CASPR2, contactin-2) and the NMDA, AMPA, GABA B and Glycine receptors This increasingly recognised category is much less frequently associated with malignancy, and the neurological disease is thought to be mediated by the antibodies themselves. These diseases tend to have a better response to immunotherapy. The first recognised syndrome in this category was the VGKC-complex antibody syndrome 8 .
CLINICAL PICTURE
The cardinal signs of AIE are the impairment of short-term memory, usually developing over weeks or months, psychiatric symptoms (irritability, depression and hallucinations) and mesiotemporal seizures [5] [6] [7] [8] [9] . Apart from this typical "limbic syndrome", there are other associated neurological features, which often reflect the presence of different associated antibodies.
Antibodies to intracellular antigens
Hu (ANNA-1) -this type can involve any part of the nervous system, including peripheral nerves, dorsal root ganglia and spinal cord. A smoking history is often present as 75% of patients have small cell lung carcinoma (SCLC) 10 . The prognosis is usually poor despite immunotherapy.
Ma2 -the clinical clues are the presence of both hypothalamic (daytime sleepiness, narcolepsy, cataplexy, hyperphagia, hormonal deficits) and brainstem dysfunction (particularly with supranuclear gaze palsy) 11 . It occurs mostly in association with testicular germinal cell tumour in younger males, but in older individuals there may be an underlying non-small cell lung carcinoma or breast cancer 12 . Men with Ma2-antibody encephalitis in whom there is no detectable testicular tumour may have a microscopic tumour below the detection threshold of imaging techniques. For this reason, orchidectomy may be necessary in face of clinical deterioration, de novo testicular enlargement, previous cryptorchidism or ultrasound evidence of testicular microcalcification, in the absence of other tumours 8 . MRI may show contrast enhancement 13 . CV2 -the presence of chorea 14 is highly suggestive. It may also occur with involvement of other systems, commonly the visual system (uveitis, optic neuritis). There may be an underlying SCLC, malignant thymoma or other tumours.
GAD -although GAD is an intracellular enzyme, antibodies directed against this enzyme are usually associated with a non-paraneoplastic AIE [15] [16] [17] . It tends to occur in women without any identified tumour. Drug resistant epilepsy is common 15 and GAD-antibodies are also associated with the stiff-person syndrome and ataxia 16 . These antibodies are very common in other autoimmune disorders, typically DM1, often at lower levels [15] [16] [17] [18] .
Antibodies to cell membrane antigens
The most common syndromes NMDAR -this appears to be one of the most frequent AIE 19 . It was initially described in young women with ovarian teratomas 20 , of which 70% were benign. Nevertheless, it is now known that it also frequently affects men and children 21 . The presence of a tumour is more frequent in black women older than 18 years 19 and rare in paediatric populations. The characteristic clinical picture starts with a psychotic stage (many patients are initially seen by psychiatrists) and seizures, followed by reduction in consciousness, autonomic instability (which includes fluctuation of blood pressure and temperature, tachycardia, bradycardia, cardiac pauses and diaphoresis) and movement disorders, namely dyskinesias. The oral-lingual-facial dyskinesias 19 are the most characteristic, but other abnormal movements, such as opisthotonic postures and a catatonic state 22 , may also occur. A curious feature is a dissociative response to stimuli: patients may resist eye opening, but show reduced or absent response to painful stimuli 23 . Invasive ventilation and admission to an intensive care unit are frequently necessary. LGI1 GAD
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Disease relapses may occur in 15-25% of cases, especially in non-paraneoplastic cases without adequate immunotherapy during their previous encephalitic episode 21, 24, 25 . As far as investigations are concerned, CSF typically reveals an early lymphocytic pleocytosis followed by intrathecal synthesis of antibodies 21, 26 . The MRI is frequently normal, however changes can be seen in medial temporal lobes and in white matter 19, 21 .
VGKC-complex (
LGI1, CASPR2, Contactin-2) -it has been recently recognized that VGKC antibodies are directed to particular components of the VGKC-complex, most commonly LGI1, CASPR2 and Contactin-2 5, 6, 27 . In VGKC-complex associated AIE, most antibodies are directed against LGI1, but a minority have CASPR2 antibodies 5 . Patients show a male:female ratio of 2:1 and are typically older than 40 years 27 . This encephalitis may also present with rapid eye movement sleep behaviour disorder, hypothermia 28 , startle syndrome, ataxia and intestinal pseudoobstruction. A recently described and highly distinctive feature is the presence of faciobrachial dystonic seizures (FBDS), characterized by brief and frequent dystonic paroxysms typically involving the face and ipsilateral arm; these patients consistently have antibodies against LGI1 6 . In VGKC-complex antibody AIE, MRI typically reveals hyperintensity best appreciated in T2 and FLAIR sequences in the mesiotemporal lobes. However, around 40% of cases have a normal MRI 27 , and the CSF tends to show the absence of pleocytosis or intrathecal synthesis. Another distinguishing feature is the presence of hyponatremia in around 50% of cases, usually with a SIADH pattern. Only a few VGKCcomplex antibody positive patients have tumours, typically SCLC or thymoma 26 . In contrast to NMDAR-antibody positive patients, relapses are unusual in those with antibodies against VGKC-complexes. Patients with an encephalopathy and prominent insomnia, neuromyotonia and dysautonomia are often termed Morvan' s syndrome. These patients show high levels of CASPR2-antibodies, often with lower levels of LGI1-antibodies 29 
.
Morvan' s patients have a high risk of an underlying tumour which is usually a thymoma: the majority of patients with a tumour have CASPR2 antibodies 29 .
Less frequent syndromes AMPAR -this antibody has been identified in women with relapsing AIE. Of patients, 64% had an underlying tumour, and the SCLC are the most common 18, 30 . CSF typically shows pleocytosis and intrathecal synthesis of antibodies.
GABA B R -clinically fairly typical apart from early and prominent epileptic seizures 5 . Despite being membrane antibodies, they have been reported to commonly associate with SCLC 31 . GlycineR -patients may present with progressive encephalomyelitis with rigidity and myoclonus (PERM) 24 , a rare condition showing limb and axial rigidity, muscle spasms, brainstem signs and hyperekplexia [32] [33] [34] . Investigations may show CSF with inflammatory changes, and MRI has been normal in all of the published clinical reports 33, 34 . mGluR5 -the two published cases had Hodgkin lymphoma (ophelia syndrome). The clinical picture is reasonably typical, the CSF shows pleocytosis and MRI, apart from limbic involvement, may show parietal and occipital cortex changes 35 .
DIAGNOSIS
AIE has a wide differential diagnosis. One way of trying narrow-down the possibilities is to create a rational plan of investigations guided by an accurate clinical history, in an attempt to identify the key points already described.
As far as the diagnosis is concerned, the first step is to consider other treatable disorders, such as viral encephalitis and systemic autoimmune diseases. Secondly, the basic workup includes the following investigations:
(1) MRI -signal changes of medial temporal lobes, best seen in T2 and FLAIR sequences. Often no changes are seen on MRI.
(2) CSF -typically with inflammatory changes as lymphocytic pleocytosis, high protein and oligloconal bands. However, in many conditions, these changes are not present. The combination of the clinical picture and the above laboratory investigations often suggests the diagnosis of AIE, but normal results do not exclude it (particularly normal CSF analysis and MRI). Brain fluorodeoxyglucose PET scan may be useful as it may show hypermetabolic changes in the temporal lobes when the MRI is still normal 21, 36 . One should bear in mind that in 60-70% of the paraneoplastic cases, the neurological picture precedes the symptoms related to the cancer. One valuable approach is screening with body imaging such as a CT and/or a PET scan. Additionally, testicular ultrasound in men and mammography/mammary ultrasound in women should be performed when appropriate.
The final step is to detect the autoantibodies either in serum or CSF. In almost all patients, serum shows higher concentrations of antibodies than CSF. It is worth discussing the preferred sample with your diagnostic laboratory as the methods of detection may determine the sample of choice 37 .
As there is a constant discovery of new antibodies and an increasing heterogeneity regarding the clinical picture, it may be tricky to decide which antibody to test. Both past medical history and clinical presentation are critical in guiding the optimal approach. There are features that help to distinguish subtypes, for example, hyponatremia ad initium (a consequence of the syndrome of inappropriate ADH secretion) and acellular CSF in VGKC-complex antibody mediated encephalitis and the combination of a normal MRI and severe encephalopathy with a movement disorder in NMDAR antibody patients.
Different diagnostic criteria have already been proposed 7, 9, 38, 39 and the aim of the following diagram (Fig 2) was to simplify the diagnostic workup. Its rationale is to firstly exclude alternative treatable conditions (such as herpes simplex encephalitis) and, secondly, to determine which antibody is likeliest given the clinical phenotype.
TREATMENT
When autoimmune encephalitis is considered likely, treatment should be started promptly. Also, a trial of immunotherapy may serve as a valuable "diagnostic test". However, some conditions are typically refractory to initial immunotherapy administration (e.g. NMDAR-antibody encephalitis), and the trial should not be considered definitive proof as to the immune aetiology of the illness.
If there is an identified neoplasm, its removal may be important for the neurological improvement 7, 20, 21 . However, in traditional paraneoplastic cases associated with intracellular antibodies, there is rarely a favourable response to this approach even with immunotherapies. On the other hand, those cases of AIE associated with membrane antibodies may have a good response to immune interventions, plus tumour removal when indicated 20, 26 . IVIg, plasma exchange (PE), corticosteroids, cyclophosphamide and rituximab have all been used with success.
A typical strategy for acute therapy is IV methylprednisolone (1 g IV daily for 3-5 days) with either IVIG (0,4-1 g/kg IV daily for 3-5 days) or PE, usually followed by oral prednisolone. If there is no or only a limited response, some authors advocate second-line therapies 20 , such as rituximab and/or cyclophosphamide.
FINAL REMARKS
AIE is a relatively frequent inflammatory disorder with protean clinical manifestations in addition to a typical "limbic syndrome", reflecting the diverse likely causal antibodies. Antibodies against intracellular antigens tend to be associated with underlying malignancies. On the other hand, those directed to membrane antigens are usually not associated with tumours and have a better prognosis. However, such categorization is somewhat artificial, because membrane autoantibodies may also be associated with tumours.
As there are so many associated neurological symptoms, an accurate clinical history is mandatory for the correct investigation of the underlying autoantibody. Many of the clinical and investigation features strongly predict the underlying antibody and hence the association with tumours and potential response to immunotherapies. There are some precious clues, as the presence of hyponatremia and faciobrachial dystonic seizures with VGKC complex antibodies or psychiatric onset, movement disorders and dissociative responses with NMDAR antibodies. The phenotype may help clinicians to make a rational decision regarding antibody testing.
The identification of an encephalopathy with an autoimmune pathogenesis and, therefore, a potential response to immunotherapy is of great importance as successful treatments are possible. Notwithstanding, pharmacological management remains empirical, and prospective studies are needed to determine the optimal drug regimen.
